JP2023533855A - イソキノリン化合物およびそのＡｈＲ不均衡の治療への使用 - Google Patents

イソキノリン化合物およびそのＡｈＲ不均衡の治療への使用 Download PDF

Info

Publication number
JP2023533855A
JP2023533855A JP2023502881A JP2023502881A JP2023533855A JP 2023533855 A JP2023533855 A JP 2023533855A JP 2023502881 A JP2023502881 A JP 2023502881A JP 2023502881 A JP2023502881 A JP 2023502881A JP 2023533855 A JP2023533855 A JP 2023533855A
Authority
JP
Japan
Prior art keywords
optionally substituted
alkyl
compound
formula
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023502881A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023533855A5 (https=
Inventor
アックスマン、アリソン
エイチ． ドリューリー、デイビッド
ケイ． ジャヤウィックリーム、チャンナ
セレンスキー、キャロリン
エイチ． スミス、スーザン
ポール トランプ、ライアン
ウェルズ、カロウ
ウィルソン、ティモシー
ジャン、カンユ
ズアーチャー、ウィリアム
Original Assignee
ダーマヴァント サイエンシーズ ゲーエムベーハー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ダーマヴァント サイエンシーズ ゲーエムベーハー filed Critical ダーマヴァント サイエンシーズ ゲーエムベーハー
Publication of JP2023533855A publication Critical patent/JP2023533855A/ja
Publication of JP2023533855A5 publication Critical patent/JP2023533855A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/18—Aralkyl radicals
    • C07D217/20—Aralkyl radicals with oxygen atoms directly attached to the aromatic ring of said aralkyl radical, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
JP2023502881A 2020-07-16 2021-05-27 イソキノリン化合物およびそのＡｈＲ不均衡の治療への使用 Pending JP2023533855A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063052574P 2020-07-16 2020-07-16
US202063052561P 2020-07-16 2020-07-16
US63/052,574 2020-07-16
US63/052,561 2020-07-16
PCT/US2021/034599 WO2022015423A1 (en) 2020-07-16 2021-05-27 ISOQUINOLINE COMPOUNDS AND THEIR USE IN TREATING AhR IMBALANCE

Publications (2)

Publication Number Publication Date
JP2023533855A true JP2023533855A (ja) 2023-08-04
JP2023533855A5 JP2023533855A5 (https=) 2025-09-12

Family

ID=79293345

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023502881A Pending JP2023533855A (ja) 2020-07-16 2021-05-27 イソキノリン化合物およびそのＡｈＲ不均衡の治療への使用

Country Status (10)

Country Link
US (5) US11267788B2 (https=)
EP (1) EP4185566A4 (https=)
JP (1) JP2023533855A (https=)
KR (1) KR20230041021A (https=)
CN (1) CN116157387A (https=)
AU (1) AU2021308209A1 (https=)
CA (1) CA3185793A1 (https=)
IL (1) IL299756A (https=)
MX (1) MX2023000263A (https=)
WO (1) WO2022015423A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026083733A1 (ja) * 2024-10-18 2026-04-23 株式会社ヤクルト本社 試験方法、ゲル状組成物、及び試験装置

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023533855A (ja) 2020-07-16 2023-08-04 ダーマヴァント サイエンシーズ ゲーエムベーハー イソキノリン化合物およびそのＡｈＲ不均衡の治療への使用
WO2024020170A1 (en) * 2022-07-21 2024-01-25 Allianthera (Suzhou) Biopharmaceutical Co., Ltd. Aryl hydrocarbon receptor agonist prodrugs and methods of use thereof
US20260069585A1 (en) * 2022-08-30 2026-03-12 Dermavant Sciences GmbH ISOQUINOLINE COMPOUNDS AND THEIR USE IN TREATING AhR MEDIATED DISEASES
WO2024152993A1 (zh) * 2023-01-17 2024-07-25 上海泽德曼医药科技有限公司 稠环类化合物、其制备方法及其在医药上的应用
CN117447402A (zh) * 2023-10-18 2024-01-26 德明药泰生物技术（深圳）有限公司 芳香烃受体调节剂类化合物及其制备方法和应用
CN117229208B (zh) * 2023-11-13 2024-02-23 上海泽德曼医药科技有限公司 稠环类化合物、其制备方法及其在医药上的应用

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999018077A1 (en) * 1997-10-02 1999-04-15 Eisai Co., Ltd. Fused pyridine derivatives
WO2003053359A2 (en) * 2001-12-19 2003-07-03 Atherogenics, Inc. 1,3-bis-(substituted-phenyl)-2-propyn-1-ones and their use to treat disorders
JP2005516941A (ja) * 2001-12-19 2005-06-09 アセロジエニクス・インコーポレイテツド カルコン誘導体及び疾患を治療するためのそれらの使用
WO2011156626A1 (en) * 2010-06-09 2011-12-15 Rutgers, The State University Of New Jersey Antimicrobial agents
WO2019018562A1 (en) * 2017-07-19 2019-01-24 Ideaya Biosciences, Inc. AMIDO COMPOUND AS MODULATORS OF AHR
WO2019158453A1 (de) * 2018-02-13 2019-08-22 Merck Patent Gmbh Metallkomplexe
JP2020515604A (ja) * 2017-03-29 2020-05-28 メルク、パテント、ゲゼルシャフト、ミット、ベシュレンクテル、ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ ＧｍｂＨ 金属錯体

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992018123A2 (en) 1991-04-10 1992-10-29 Octamer, Inc. A method for inhibition of retroviral replication
US5919970A (en) 1997-04-24 1999-07-06 Allergan Sales, Inc. Substituted diaryl or diheteroaryl methanes, ethers and amines having retinoid agonist, antagonist or inverse agonist type biological activity
HRP20040102A2 (en) 2001-07-09 2004-10-31 Combinatorx Combinations for the treatment of inflammatory disorders
JPWO2005063222A1 (ja) 2003-12-26 2007-07-19 協和醗酵工業株式会社 Ｈｓｐ９０ファミリー蛋白質阻害剤
WO2006058201A2 (en) 2004-11-23 2006-06-01 Reddy Us Therapeutics, Inc. Heterocyclic and bicyclic compounds, compositions and methods
GB0704718D0 (en) 2007-03-12 2007-04-18 Prendergast Patrick T Compounds and methods for preventing and treating mucositis
EP2014651A1 (en) 2007-07-12 2009-01-14 Exonhit Therapeutics SA Compounds and methods for modulating Rho GTPases
JP5439127B2 (ja) 2009-11-13 2014-03-12 株式会社さいわいメディカル 乾癬又はアトピー性皮膚炎治療剤
GB201216017D0 (en) * 2012-09-07 2012-10-24 Cancer Rec Tech Ltd Inhibitor compounds
AU2013361314A1 (en) 2012-12-20 2015-07-02 Aldeyra Therapeutics, Inc. Peri-carbinols
GB201304041D0 (en) 2013-03-06 2013-04-17 Water Jel Europ Llp Treatment and prophylaxis of radiation dermatitis
US10626094B2 (en) 2014-10-14 2020-04-21 Sanford Burnham Prebys Medical Discovery Institute Inhibitors of low molecular weight protein tyrosine phosphatase and uses thereof
TWI828664B (zh) 2018-03-19 2024-01-11 愛爾蘭商Ｕｄｃ愛爾蘭責任有限公司 金屬錯合物
JP2023533855A (ja) 2020-07-16 2023-08-04 ダーマヴァント サイエンシーズ ゲーエムベーハー イソキノリン化合物およびそのＡｈＲ不均衡の治療への使用
WO2023020512A1 (zh) * 2021-08-16 2023-02-23 成都奥睿药业有限公司 取代的吡啶类似物、其制备方法及作为ahr调节剂的用途
CN116947799B (zh) * 2023-03-08 2024-05-03 上海泽德曼医药科技有限公司 酚类化合物、其制备方法及其在医药上的应用

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999018077A1 (en) * 1997-10-02 1999-04-15 Eisai Co., Ltd. Fused pyridine derivatives
WO2003053359A2 (en) * 2001-12-19 2003-07-03 Atherogenics, Inc. 1,3-bis-(substituted-phenyl)-2-propyn-1-ones and their use to treat disorders
JP2005516941A (ja) * 2001-12-19 2005-06-09 アセロジエニクス・インコーポレイテツド カルコン誘導体及び疾患を治療するためのそれらの使用
WO2011156626A1 (en) * 2010-06-09 2011-12-15 Rutgers, The State University Of New Jersey Antimicrobial agents
JP2020515604A (ja) * 2017-03-29 2020-05-28 メルク、パテント、ゲゼルシャフト、ミット、ベシュレンクテル、ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ ＧｍｂＨ 金属錯体
WO2019018562A1 (en) * 2017-07-19 2019-01-24 Ideaya Biosciences, Inc. AMIDO COMPOUND AS MODULATORS OF AHR
WO2019158453A1 (de) * 2018-02-13 2019-08-22 Merck Patent Gmbh Metallkomplexe

Non-Patent Citations (13)

* Cited by examiner, † Cited by third party
Title
CHURRUCA, F. ET AL.: "Direct, Two-Step Synthetic Pathway to Novel Dibenzo[a,c]phenanthridines", J. ORG. CHEM., JPN6025022242, 2005, ISSN: 0005609397 *
FITZGERALD, J. J. ET AL.: "Reaction of benzocyclobutene oxides with nitriles: synthesis of hypecumine and other 3-substituted i", TETRAHEDRON LETTERS, vol. 35, no. 49, JPN6025022239, 1994, ISSN: 0005760068 *
HUANG, Q. ET AL.: "Synthesis of Substituted Isoquinolines by Electrophilic Cyclization of Iminoalkynes", JOURNAL OF ORGANIC CHEMISTRY, vol. 67, no. 10, JPN6025022234, 2002, pages 3437 - 3444, ISSN: 0005760063 *
HUI, W. AND DAI, Y.: "Therapeutic potential of aryl hydrocarbon receptor ligands derived from natural products in rheumato", BASIC CLIN PHARMACOL TOXICOL., vol. 126, JPN6025022244, 2020, pages 469 - 474, ISSN: 0005609399 *
KHADKA, D. B. ET AL.: "Design, synthesis, and biological evaluation of 1,3-diarylisoquinolines as novel topoisomerase I cat", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, vol. 143, JPN6025022236, 2018, pages 200 - 215, ISSN: 0005760065 *
KHADKA, D. B. ET AL.: "Modification of 3-arylisoquinolines into 3,4-diarylisoquinolines and assessment of their cytotoxicit", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, vol. 92, JPN6025022241, pages 583 - 607, ISSN: 0005609396 *
KIM, A. N. ET AL.: "Iridium-Catalyzed Enantioselective and Diastereoselective Hydrogenation of 1,3-Disubstituted Isoquin", ACS CATALYSIS, vol. 10, no. 5, JPN6025022235, 2020, pages 3241 - 3248, ISSN: 0005760064 *
MISHRA, P. K. ET AL.: "Harnessing the reactivity of ortho-formyl-arylketones: base-promoted regiospecific synthesis of func", CHEMICAL COMMUNICATIONS (CAMBRIDGE, UNITED KINGDOM), vol. 55, no. 57, JPN6025022245, 2019, pages 8278 - 8281, ISSN: 0005760062 *
SMITH, S. H. ET AL.: "Tapinarof Is a Natural AhR Agonist that Resolves Skin Inflammation in Mice and Humans", JOURNAL OF INVESTIGATIVE DERMATOLOGY, vol. 137, no. 10, JPN6025022240, 2017, pages 2110 - 2119, ISSN: 0005609395 *
SMUTNY, T. ET AL.: "2-(3-Methoxyphenyl)quinazoline Derivatives: A New Class of Direct Constitutive Androstane Receptor (", JOURNAL OF MEDICINAL CHEMISTRY, vol. 59, no. 10, JPN6025022246, 2016, pages 4601 - 4610, ISSN: 0005609400 *
STEJSKALOVA, L. ET AL.: "Endogenous and Exogenous Ligands of Aryl Hydrocarbon Receptor: Current State of Art", CURRENT DRUG METABOLISM, vol. 12, JPN6025022243, 2011, pages 198 - 212, ISSN: 0005609398 *
TIWARI, V. K. ET AL.: "One substrate, two modes of C-H functionalization: a metal-controlled site-selectivity switch in C-H", ORGANIC LETTERS, vol. 19, no. 1, JPN6025022237, 2017, pages 262 - 265, ISSN: 0005760066 *
YANG, S. H. ET AL.: "Synthesis, in vitro and in vivo evaluation of 3-arylisoquinolinamines as potent antitumor agents", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 20, no. 17, JPN6025022238, 2010, pages 5277 - 5281, ISSN: 0005760067 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026083733A1 (ja) * 2024-10-18 2026-04-23 株式会社ヤクルト本社 試験方法、ゲル状組成物、及び試験装置

Also Published As

Publication number Publication date
US20240208910A1 (en) 2024-06-27
EP4185566A4 (en) 2024-12-04
KR20230041021A (ko) 2023-03-23
US20250282730A1 (en) 2025-09-11
MX2023000263A (es) 2023-03-29
US11827605B2 (en) 2023-11-28
AU2021308209A8 (en) 2023-04-13
IL299756A (en) 2023-03-01
CN116157387A (zh) 2023-05-23
AU2021308209A1 (en) 2023-02-09
US12252471B2 (en) 2025-03-18
CA3185793A1 (en) 2022-01-20
WO2022015423A1 (en) 2022-01-20
US20220153703A1 (en) 2022-05-19
US11267788B2 (en) 2022-03-08
US11548853B2 (en) 2023-01-10
EP4185566A1 (en) 2023-05-31
US20230124135A1 (en) 2023-04-20
US20220017468A1 (en) 2022-01-20

Similar Documents

Publication Publication Date Title
JP2023533855A (ja) イソキノリン化合物およびそのＡｈＲ不均衡の治療への使用
JP5820921B2 (ja) １，２−二置換複素環式化合物
US20130281396A1 (en) Treatment of diseases by epigenetic regulation
EP3210969B1 (en) Kcnq2-5 channel activator
HUP0303624A2 (hu) NEP inhibitor hatású N-fenpropil-ciklopentil-csoporttal szubsztituált glutáramid származékok és ezeket tartalmazó gyógyászati készítmények és eljárás a vegyületek előállítására
US11299497B2 (en) Substituted tetrahydropyran dihydrothienopyrimidines and their use as phosphodiesterase inhibitors
WO2015032328A1 (zh) 茚满衍生物及其制备方法和在医药上的应用
EP3532062B1 (en) Ror-gamma modulators
US11384096B2 (en) Substituted azetidine dihydrothienopyridines and their use as phosphodiesterase inhibitors
JP3826400B2 (ja) ラクタム化合物及びその医薬用途
JPWO2007000998A1 (ja) ビス（アリールメチリデン）アセトン化合物、抗癌剤、発癌予防剤、Ｋｉ−Ｒａｓ、ＥｒｂＢ２、ｃ−Ｍｙｃ及びＣｙｃｌｉｎＤ１の発現抑制剤、β−カテニン分解剤並びにｐ５３の発現増強剤
US9896415B2 (en) Chalcone derivatives having an anti-allergic activity
CN117999072A (zh) β肾上腺素能激动剂和其使用方法
JP2009051731A (ja) 新規アスコクロリン誘導体化合物及びそれを含有する医薬組成物
AU2024347494A1 (en) Use of heterocyclic compound in preparation of drug for preventing and/or treating kidney disease
WO2025237171A1 (zh) 嘧啶并五元氮杂环酚类化合物及其应用
JP2025529076A (ja) ＡｈＲ媒介疾患の治療に使用するタピナロおよびそのアナログ製剤
US20110098350A1 (en) Substituted cyclohexylidene-ethylidene-octahydro-indene compounds

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240524

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240524

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240610

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250529

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250603

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20250903

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20251223

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260421